Independent pharmacy owners should not have to choose between staying independent and competing at scale. Rede Soma Drogarias was built to prove they can do both. Through its association model, Rede Soma gives independent pharmacies the scale to compete without taking away the independence that makes them successful. Members gain stronger purchasing power, modern technology and professional management support while continuing to operate under their own name, make their own business decisions and remain deeply connected to the communities they serve. Instead of relying solely on the resources they can build individually, they benefit from the collective strength of a much larger network. “We act as a true extension of each pharmacy’s back office, giving owners the intelligence, support and commercial strength to run a more competitive and profitable business without giving up their independence,” says Paulo Ribeiro, CEO..

When a physician orders a genetic test, the report that comes back rarely settles anything on its own. It lists findings but does not clarify which ones matter for this patient, how to explain the results to a family still in the room, or what the next clinical step should be. That interpretive gap is where diagnoses stall and care decisions drift without firm ground. Cligen, a medical genetics clinic founded in Vitória, Brazil, in 2021, was built to close that gap. “We are a clinic before we are a laboratory,” says Dr. Arsonval Lamounier Júnior, medical director. “We place the patient and their family at the center of our approach.” That orientation changes what a physician receives. Every genetic report arrives with a clinical case interpretation. The Cligen team reviews the findings, evaluates the literature relevant to the presentation and calls the referring physician directly. The effect is that, instead of filing the report, deferring to a specialist, or delaying a care decision, the clinician gains a colleague ready to reason through the result in real time. That conversation is what turns a genetic finding into a clinical action. Cligen also maps its referring network, recognizing that physicians vary widely in their comfort with genetics. Those working near the limits of their genomic training receive targeted education, invitations to scientific meetings and direct collaboration on complex cases. As clinicians gain confidence, they order more appropriate tests, interpret results more accurately and deliver better care. Each interaction strengthens the network’s collective genomic literacy..

A molecular structure can show researchers what a biological molecule looks like, but it cannot always explain how that molecule behaves. DNA, RNA, and other biological molecules move, change shape, and interact with their surroundings, and those dynamics can influence how they function. Understanding these changes is particularly important in biomedical research, where molecular behavior can shape everything from nucleic acid therapeutics to bacterial resistance. Investigating these questions requires approaches that connect molecular structure and dynamics with biological function. DansLab applies this approach as a fully academic research group at the University of the Republic in Uruguay, centered on computational biophysics, molecular modeling, and structural bioinformatics, with AI emerging as a newer area of its research. Led by Pablo Dans Puiggròs, principal investigator and professor, the group has more than two decades of experience studying nucleic acids, modified oligonucleotides, protein-nucleic acid complexes, and molecular recognition. Its contribution is centered on scientific research, training students and young researchers, developing and evaluating methods, sharing tools through open science, and building collaborative research connections. That academic foundation is complemented by Institut Pasteur de Montevideo, where access to biomedical researchers, experimental expertise, and specialized infrastructure brings the group closer to biological and biomedical questions. “We are not only users of computational tools. We also develop new methods, force fields, and molecular models. Our goal is to move from sequence and structure to dynamics, function, and molecular mechanism,” says Dans..

Today, advances in molecular diagnostics, personalized medicine, and biomedical technology have given physicians unprecedented insight into the biology of disease. Yet this progress has created a new challenge: the growing complexity of diagnostic decision-making. Physicians face an expanding universe of tests, platforms, and biomarkers, making it hard to determine the right test for a specific clinical question and interpret the results correctly. What they increasingly need is not simply a laboratory that generates data, but a diagnostic partner capable of transforming complex findings into clinically meaningful answers. Meeting this need has been at the heart of MediPath’s mission for the past two decades. By combining advanced molecular diagnostics, pathology expertise, research, and physician collaboration, it has built an integrated diagnostic model designed to support more informed clinical decisions across Latin America. “We see ourselves as a diagnostic partner, not just a testing provider,” says Argelia Aybar, medical director and founder. “Our pathologists work with physicians to discuss cases, explain testing capabilities, help identify the most appropriate tests and interpret results with confidence.” From Advanced Testing to Clinical Decision Support Founded in 2004 in the Dominican Republic, MediPath emerged during a period when many advanced molecular pathology capabilities were not available locally and specialized samples often had to be sent abroad. Its mission was to bring sophisticated diagnostic solutions closer to physicians and patients while developing the expertise to interpret these technologies locally. The organization expanded its capabilities in response to challenges identified by physicians—beginning with HPV DNA testing, followed by liquid-based cytology with ThinPrep, immunohistochemistry, flow cytometry, real-time PCR, and additional molecular diagnostic applications..

Flex Databases has established itself as a leading provider of unified eClinical solutions designed to streamline and strengthen clinical operations for pharmaceutical and medical device organizations. At its core is a single, integrated platform that brings together essential technologies, such as CTMS, eTMF, EDC, QMS, and Pharmacovigilance, into a coherent ecosystem. Together, these modules form a connected operational foundation that supports the full lifecycle of modern clinical trials. In 2025, the average number of modules implemented per client increased by 35 percent, signaling a decisive trend: organizations are consolidating their clinical operations under a single, interconnected environment rather than juggling multiple vendors and fragmented workflows. Several major pharmaceutical and medical device companies have selected Flex Databases specifically for its ability to deliver a fully integrated system, combining CTMS, eTMF, QMS, Pharmacovigilance, Project Management, EDC, and more, within a single cohesive architecture. “We empower life sciences with a secure, unified all in one eClinical platform, delivering flexibility, scalability and efficiency across clinical operations worldwide,” says Marietta Sarkisyan, Global Director, Business Development. Unified Clinical Excellence The complexity of modern clinical research has made it nearly impossible to manage studies effectively without fully integrated systems. When CTMS, eTMF, safety, quality, learning, and financial tools are sourced from different providers, organizations face mounting inefficiencies: redundant data entry, inconsistent workflows, higher training costs and increased risk of operational gaps. Flex Databases eliminates these burdens by centralizing the full clinical lifecycle within one seamless platform. Every component, from EDC and ePRO to Pharmacovigilance, QMS, and a fully exportable TMF, works together through interconnected data flows, electronic signatures, and standardized oversight mechanisms..